| Literature DB >> 24289295 |
Enola K Proctor1, Byron J Powell, J Curtis McMillen.
Abstract
Implementation strategies have unparalleled importance in implementation science, as they constitute the 'how to' component of changing healthcare practice. Yet, implementation researchers and other stakeholders are not able to fully utilize the findings of studies focusing on implementation strategies because they are often inconsistently labelled and poorly described, are rarely justified theoretically, lack operational definitions or manuals to guide their use, and are part of 'packaged' approaches whose specific elements are poorly understood. We address the challenges of specifying and reporting implementation strategies encountered by researchers who design, conduct, and report research on implementation strategies. Specifically, we propose guidelines for naming, defining, and operationalizing implementation strategies in terms of seven dimensions: actor, the action, action targets, temporality, dose, implementation outcomes addressed, and theoretical justification. Ultimately, implementation strategies cannot be used in practice or tested in research without a full description of their components and how they should be used. As with all intervention research, their descriptions must be precise enough to enable measurement and 'reproducibility.' We propose these recommendations to improve the reporting of implementation strategies in research studies and to stimulate further identification of elements pertinent to implementation strategies that should be included in reporting guidelines for implementation strategies.Entities:
Mesh:
Year: 2013 PMID: 24289295 PMCID: PMC3882890 DOI: 10.1186/1748-5908-8-139
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Prerequisites to measuring implementation strategies
| Name the strategy, preferably using language that is consistent with existing literature. | Cochrane EPOC
[ | |
| Mazza | ||
| Powell | ||
| Define the implementation strategy and any discrete components operationally | Abraham & Michie
[ | |
| Powell | ||
| Michie | ||
| | | |
| a) The actor | Identify who enacts the strategy ( | Kauth |
| b) The action | Use active verb statements to specify the specific actions, steps, or processes that need to be enacted. | Rapp |
| c) Action target | Specify targets according to conceptual models of implementation | Tabak |
| Damschroder | ||
| Identify unit of analysis for measuring implementation outcomes | ||
| Flottorp | ||
| Cane | ||
| Michie | ||
| Landsverk | ||
| Proctor | ||
| d) Temporality | Specify when the strategy is used | Magnabosco
[ |
| Chinman | ||
| Kilbourne | ||
| e) Dose | Specify dosage of implementation strategy | Atkins |
| f) Implementation outcome affected | Identify and measure the implementation outcome(s) likely to be affected by each strategy | Proctor |
| Proctor & Brownson
[ | ||
| Proctor | ||
| g) Justification | Provide empirical, theoretical, or pragmatic justification for the choice of implementation strategies. | Theoretical: |
| Eccles | ||
| Grol | ||
| Empirical: | ||
| Cochrane EPOC
[ | ||
| Grimshaw | ||
| Pragmatic: | ||
| Oxman | ||
| Wensing |
Specification of two implementation strategies
| Actor(s) | Clinician who is expert in the clinical innovation and recommended by the treatment developer. | A team of clinicians who are implementing the clinical innovation. |
| Action(s) | Provides clinical supervision via phone to answer questions, review case implementation, make suggestions, and provide encouragement. | Reflect on the implementation effort, share lessons learned, support learning, and propose changes to be implemented in small cycles of change. |
| Target(s) of the action | Clinicians newly trained in the innovation. | Clinicians newly trained in the innovation. |
| Knowledge about the innovation, skills to use the innovation, optimism that the innovation will be effective, and improved ability to access details about how to use the innovation without prompts. | Knowledge about how to use the innovation in this context, intentions to use the innovation, social influences. | |
| Temporality | Clinical supervision should begin within one week following the end of didactic training. | First meeting should be within two weeks of initial training. |
| Dose | Once per week for 15 minutes for 12 weeks, plus follow-up booster sessions at 20 and 36 weeks. | Once monthly for one hour for the first six months. |
| Implementation outcome(s) affected | Uptake of the innovation, penetration among eligible clients/patients, fidelity to the protocol of the clinical innovation. | Uptake of the innovation, penetration among eligible clients/patients, fidelity to the protocol of the clinical innovation, sustainability of the innovation. |
| Justification | Research that suggests that post-training coaching is more important than quality or type of training received
[ | Cooperative learning theory
[ |